Joint with: Cancer Immunotherapy: Clinical Lessons to New Modalities
Immune Cell Therapies: Advances in Cancer and Autoimmune Disease
March 16-19, 2025 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Katy Rezvani, Nathan Singh and Stephan Mielke
In Person
On Demand
March 16-19, 2025 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Katy Rezvani, Nathan Singh and Stephan Mielke
Available Formats:
In Person
On Demand
Supported by the Directors' Fund
Available Formats: = In Person = On Demand
Merchandise Options
Registration Options
Sunday, March 16, 2025
Booking Function
Fundraising
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Monday, March 17, 2025
Breakfast
7:00–8:00 AM
Welcome and Keynote Session (Joint)
8:00–9:30 AM
Carl H. June, University of Pennsylvania
Cell Therapies: Current State-of the Art
Cell Therapies: Current State-of the Art
Ton N. Schumacher, Netherlands Cancer Institute
Dissecting T Cell Recognition of Cancer
Dissecting T Cell Recognition of Cancer
Overcoming Challenges in Immune and Cell Therapy: Insights into Mechanisms of Failure and Solutions (Joint)
9:30–11:30 AM
Coffee Break
9:30–9:50 AM
Nathan Singh, Washington University School of Medicine
Genomic Regulation of CAR-Driven T Cell Dysfunction
Genomic Regulation of CAR-Driven T Cell Dysfunction
Shannon J. Turley, Genentech, Inc.
CAF Targeting
CAF Targeting
Anna Christina Obenauf, Research Institute of Molecular Pathology
Rational Combination of Therapies to Stimulate the APC Compartment
Rational Combination of Therapies to Stimulate the APC Compartment
May Daher, MD Anderson Cancer Center
Metabolic Interventions to Enhance Adoptive Cellular Therapies
Metabolic Interventions to Enhance Adoptive Cellular Therapies
Short Talk(s) Chosen from Abstracts
Poster Setup
11:30–1:00 PM
On Own for Lunch
11:30–5:00 PM
Poster Viewing
1:00–10:00 PM
Workshop 1: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Short Talk(s) Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Cell Therapies for Solid Tumors
5:00–7:00 PM
Michelle Monje, Stanford University
Targeting Pediatric Brain Cancers
Targeting Pediatric Brain Cancers
Marcela V. Maus, Harvard Medical School
Driving Complex CAR-T into the Clinic – What, Why, and How
Driving Complex CAR-T into the Clinic – What, Why, and How
Mark E. Dudley, Instil Bio
2nd Generation TIL Therapies
2nd Generation TIL Therapies
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Tuesday, March 18, 2025
Breakfast
7:00–8:00 AM
Diversity, Access and Pathways to Regulatory Approval
8:00–11:00 AM
Stephan Mielke, Karolinska Institutet
CAR T Cells: A European Perspective
CAR T Cells: A European Perspective
Heather Lombardi, FDA HHS
Regulatory Considerations for Cell Therapies
Regulatory Considerations for Cell Therapies
Jen Chow, Chimeric Therapeutics
Commercially Conscious Development of Cell Therapies
Commercially Conscious Development of Cell Therapies
Rayne H. Rouce, Baylor College of Medicine
Improving Access to Cell Therapies
Improving Access to Cell Therapies
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
On Own for Lunch
11:00–5:00 PM
Poster Setup
11:00–1:00 PM
Poster Viewing
1:00–10:00 PM
Career Roundtable (Joint)
3:00–4:30 PM
Coffee Available
4:30–5:00 PM
Cell Therapy for Autoimmune Diseases
5:00–7:00 PM
Andreas Mackensen, Universitätsklinikum Erlangen
CAR T Cells for SLE
CAR T Cells for SLE
Gwendolyn Binder, Cabaletta Bio
Clinical and Translational Development of Engineered T Cell Therapy for Autoimmune Disease
Clinical and Translational Development of Engineered T Cell Therapy for Autoimmune Disease
Megan K. Levings, University of British Columbia
CAR Tregs
CAR Tregs
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Wednesday, March 19, 2025
Breakfast
7:00–8:00 AM
Alternative Immune Effectors
8:00–11:00 AM
Katy Rezvani, University of Texas MD Anderson Cancer Center
Engineering NK Cells for Cancer Immunotherapy
Engineering NK Cells for Cancer Immunotherapy
Michael Klichinsky, Carisma Therapeutics
CAR-M: Engineering Myeloid Cells ex vivo and in vivo for Cancer Immunotherapy
CAR-M: Engineering Myeloid Cells ex vivo and in vivo for Cancer Immunotherapy
Bob Valamehr, Fate Therapeutics
iPSCs for Cell Therapy
iPSCs for Cell Therapy
Jurgen Kuball, University Medical Center
Mastering Diversity of gdT Cells and the Receptors for Cancer Immune Therapies
Mastering Diversity of gdT Cells and the Receptors for Cancer Immune Therapies
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
On Own for Lunch
11:00–5:00 PM
Workshop 2: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Short Talk(s) Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Engineering in Cancer Immunotherapy to Enhance Efficacy (Joint)
5:00–6:45 PM
Jaehyuk Choi, Northwestern University
Talk Title to be Announced
Talk Title to be Announced
Rosandra Natasha Kaplan, NCI, National Institutes of Health
Engineering of Myeloid Cells
Engineering of Myeloid Cells
Julia Carnevale, University of California, San Francisco
CRISPR-Based T Cell Editing to Enhance Cell Therapy
CRISPR-Based T Cell Editing to Enhance Cell Therapy
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Social Hour with Lite Bites
7:00–8:00 PM
Entertainment
8:00–11:00 PM
Cash Bar
8:00–11:00 PM
Thursday, March 20, 2025
Departure
12:00–11:59 PM
Subscribe for Updates